In the Claims

Claims 1-27 (Cancelled).

Claim 28 (Previously Presented). A peptide of the sequence X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y wherein X is selected from the group consisting of acetyl, n-butanoyl, n-hexanoyl, n-octanoyl, lauroyl, myristoyl, palmitoyl, isohexanoyl, cyclohexanoyl, cyclopentylcarbonyl, n-heptanoyl, n-decanoyl, n-undecanoyl and 3,7-dimethyloctanoyl and Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutically acceptable salt thereof.

Claim 29 (Previously Presented). A peptide of the sequence Acetyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:2) or a pharmaceutically acceptable salt thereof.

Claim 30 (Previously Presented). A peptide of the sequence n-Butanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:3) or a pharmaceutically acceptable salt thereof.

Claim 31 (Previously Presented). A peptide of the sequence n-Octanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:4) or a pharmaceutically acceptable salt thereof.

Claim 32 (Previously Presented). A peptide of the sequence Myristoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:5) or a pharmaceutically acceptable salt thereof.

Claim 33 (Previously Presented). A peptide of the sequence Palmitoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:6) or a pharmaceutically acceptable salt thereof.

Claim 34 (Previously Presented). A composition comprising the peptide of claim 28 and a pharmaceutically acceptable carrier.

Claim 35 (Previously Presented). A composition comprising the peptide of claim 29 and a pharmaceutically acceptable carrier.

Claim 36 (Previously Presented). A composition comprising the peptide of claim

30 and a pharmaceutically acceptable carrier.

Claim 37 (Previously Presented). A composition comprising the peptide of claim 31 and a pharmaceutically acceptable carrier.

Claim 38 (Previously Presented). A composition comprising the peptide of claim 32 and a pharmaceutically acceptable carrier.

Claim 39 (Previously Presented). A composition comprising the peptide of claim 33 and a pharmaceutically acceptable carrier.

Claim 40 (Previously Presented). A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 28 in an amount effective to treat the cancer.

Claim 41 (Previously Presented). A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 29 in an amount effective to treat the cancer.

Claim 42 (Previously Presented). A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 30 in an amount effective to treat the cancer.

Claim 43 (Previously Presented). A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 31 in an amount effective to treat the cancer.

Claim 44 (Previously Presented). A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 32 in an amount effective to treat the cancer.

Claim 45 (Currently Amended). A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to

~~claim 32~~ claim 33 in an amount effective to treat the cancer.

Claim 46 (Previously Presented). The method according to any one of claims 40 to 45 further comprising administering a second polypeptide or anticancer compound.